Robert Hombach Buys 13,000 Shares of Seaport Therapeutics (NASDAQ:SPTX) Stock

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Director Robert Hombach acquired 13,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the transaction, the director owned 13,000 shares of the company’s stock, valued at $235,820. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Seaport Therapeutics Price Performance

Shares of SPTX opened at $19.36 on Friday. Seaport Therapeutics, Inc. has a 1-year low of $14.85 and a 1-year high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX) last announced its earnings results on Monday, June 8th. The company reported ($10.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($10.64) by $0.30.

Analyst Ratings Changes

Several brokerages recently issued reports on SPTX. Zacks Research upgraded shares of Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Leerink Partners initiated coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $35.00 price target on the stock. Citigroup began coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $35.00 price target for the company. Wall Street Zen upgraded Seaport Therapeutics to a “hold” rating in a report on Saturday, May 9th. Finally, Seaport Research Partners set a $42.00 price objective on Seaport Therapeutics in a research report on Tuesday, May 26th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Seaport Therapeutics has a consensus rating of “Hold” and an average target price of $35.50.